CY1107053T1 - Αρωματικες σουλφονες και η ιατρικη τους χρηση - Google Patents
Αρωματικες σουλφονες και η ιατρικη τους χρησηInfo
- Publication number
- CY1107053T1 CY1107053T1 CY20071100580T CY071100580T CY1107053T1 CY 1107053 T1 CY1107053 T1 CY 1107053T1 CY 20071100580 T CY20071100580 T CY 20071100580T CY 071100580 T CY071100580 T CY 071100580T CY 1107053 T1 CY1107053 T1 CY 1107053T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- independently
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Η εφεύρεση παρέχει ενώσεις του τύπου (Ι): όπου τα Α και Β αντιπροσωπεύουν τις ομάδες -(CH2)m- και -(CH2)n- αντιστοίχως˙ το R1 αντιπροσωπεύει υδρογόνο ή αλκύλιο με C1-6˙ το R2 αντιπροσωπεύει υδρογόνο, αλογόνο, υδροξύλιο, κυάνιο, νιτροομάδα, υδροξυ(αλκύλιο με C1-6), τριφθορομεθύλιο, τριφθορομεθοξύλιο, αλκύλιο με C1-6, αλκοξύλιο με C1-6, φθοροαλκοξύλιο με C1-6, -(CΗ2)p(κυκλοαλκύλιο με C3-6), -(CΗ2)pΟ(κυκλοαλκύλιο με C3-6), -CO(αλκύλιο με C1-6), -SO2(αλκύλιο με C1-6), -SΟ(αλκύλιο με C1-6), -S-(αλκύλιο με C1-6), -CO2(αλκύλιο με C1-6), -CO2NR5R6, -SO2NR5R6, -(CH2)pNR5R6, -(CH2)pNR5COR6, προαιρετικά υποκατασταθέντα δακτύλιο αρυλίου, προαιρετικά υποκατασταθέντα δακτύλιο ετεροαρυλίου ή προαιρετικά υποκατασταθέντα δακτύλιο ετεροκυκλυλίου· το R3 αντιπροσωπεύει προαιρετικά υποκατασταθέντα δακτύλιο αρυλίου ή προαιρετικά υποκατασταθέντα δακτύλιο ετεροαρυλίου- το R4 αντιπροσωπεύει υδρογόνο, υδροξύλιο, αλκύλιο με C1-6, αλκοξύλιο με C1-6, τροφθορομεθύλιο, τριφθορομεθοξύλιο, αλογόνο, -OSO2CF3, -(CΗ2)p(κυκλοαλκύλιο με C3-6), -(CΗ2)qΟ(αλκύλιο με C1-6) ή -(CΗ2)pΟ(κυκλοαλκύλιο με C3-6)˙ τα R5 και R6 έκαστο ανεξάρτητα αντιπροσωπεύουν υδρογόνο, αλκύλιο με C1-6 ή, μαζί με το άζωτο ή άλλα άτομα στα οποία συνδέονται, σχηματίζουν ένα δακτύλιο αζακυκλοαλκυλίου ή ένα υποκατασταθέντα από οξοομάδα δακτύλιο αζακυκλοαλκυλίου˙ το Ζ αντιπροσωπεύει -(CH2)rX- όπου η ομάδα -(CH2)r- είναι συνδεδεμένη στο R3, ή -X(CH2)r- όπου το Χ είναι συνδεδεμένο στο R3, και όπου οποιαδήποτε από τις ομάδες -CH2- δύναται να υποκατασταθεί προαιρετικά από μία ή περισσότερες ομάδες αλκυλίου με C1-6˙ το Χ αντιπροσωπεύει οξυγόνο, -NR7 ή -CH2- όπου η ομάδα -CH2- δύναται να υποκατασταθεί προαιρετικά από μία ή περισσότερες ομάδες αλκυλίου με C1-6˙ το R7 αντιπροσωπεύει υδρογόνο ή αλκύλιο με C1-6˙ τα m και n ανεξάρτητα αντιπροσωπεύουν έναν ακέραιο επιλεγόμενο από 1 και 2˙ το p ανεξάρτητα αντιπροσωπεύει έναν ακέραιο επιλεγόμενο από 0,1,2 και 3˙ το q ανεξάρτητα
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0212401A GB0212401D0 (en) | 2002-05-29 | 2002-05-29 | Compounds |
| GB0230053A GB0230053D0 (en) | 2002-12-23 | 2002-12-23 | Compounds |
| EP03755153A EP1511727B1 (en) | 2002-05-29 | 2003-05-28 | Aromatic sulfones and their medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107053T1 true CY1107053T1 (el) | 2012-10-24 |
Family
ID=29585827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100580T CY1107053T1 (el) | 2002-05-29 | 2007-04-30 | Αρωματικες σουλφονες και η ιατρικη τους χρηση |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7504392B2 (el) |
| EP (1) | EP1511727B1 (el) |
| JP (1) | JP4268126B2 (el) |
| KR (1) | KR20050013196A (el) |
| AR (1) | AR040126A1 (el) |
| AT (1) | ATE354566T1 (el) |
| AU (1) | AU2003232846B9 (el) |
| BR (1) | BR0311315A (el) |
| CA (1) | CA2486962A1 (el) |
| CY (1) | CY1107053T1 (el) |
| DE (1) | DE60311986T2 (el) |
| DK (1) | DK1511727T3 (el) |
| ES (1) | ES2279965T3 (el) |
| HK (1) | HK1075050A1 (el) |
| IL (1) | IL165330A0 (el) |
| IS (1) | IS2482B (el) |
| MX (1) | MXPA04011945A (el) |
| MY (1) | MY133587A (el) |
| NO (1) | NO330118B1 (el) |
| NZ (1) | NZ536694A (el) |
| PL (1) | PL374081A1 (el) |
| PT (1) | PT1511727E (el) |
| RU (1) | RU2327690C2 (el) |
| SI (1) | SI1511727T1 (el) |
| TW (1) | TWI281914B (el) |
| WO (1) | WO2003099786A2 (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133587A (en) | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
| MXPA04012704A (es) * | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
| GB0319235D0 (en) * | 2003-08-15 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| GB0327741D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327737D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327738D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compound |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505725D0 (en) * | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
| AU2006230602B2 (en) * | 2005-03-31 | 2010-07-15 | Amylin Pharmaceuticals, Llc | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| GB0510599D0 (en) * | 2005-05-24 | 2005-06-29 | Glaxo Group Ltd | Novel compounds |
| GB0603087D0 (en) * | 2006-02-15 | 2006-03-29 | Glaxo Group Ltd | Novel use |
| US20070293475A1 (en) * | 2006-06-20 | 2007-12-20 | Alcon Manufacturing Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| CA2742863C (en) * | 2008-11-06 | 2017-05-09 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
| CA2970502A1 (en) * | 2014-12-12 | 2016-06-16 | The Schepens Eye Research Institute, Inc. | Gdnf induction for the treatment of retinal disorders |
| US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2036213T3 (es) | 1986-10-28 | 1993-05-16 | Smith Kline & French Laboratories Limited | Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos. |
| EP0282287B2 (en) * | 1987-03-10 | 1996-04-24 | Lion Corporation | Deodorizer |
| EP0285287A3 (en) * | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| GB8717374D0 (en) | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
| US5032604A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
| GB9127041D0 (en) | 1991-12-20 | 1992-02-19 | Fujisawa Pharmaceutical Co | New use |
| GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
| WO1995023150A1 (fr) | 1994-02-25 | 1995-08-31 | Banyu Pharmaceutical Co., Ltd. | Derive de carbapendem |
| US5684195A (en) * | 1994-07-14 | 1997-11-04 | G. D. Searle & Co. | Method of preparing sulfmonamides from sulfones |
| EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
| DE19548785A1 (de) | 1995-12-27 | 1997-07-03 | Basf Ag | Saure Polyazofarbstoffe |
| ES2191838T3 (es) | 1996-05-11 | 2003-09-16 | Smithkline Beecham Plc | Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina. |
| DE69704060T2 (de) | 1996-08-14 | 2001-08-02 | Smithkline Beecham P.L.C., Brentford | Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung |
| DE19638484A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| CA2287255A1 (en) | 1997-04-22 | 1998-10-29 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| EP0937723A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| GB9804734D0 (en) * | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| US6344486B1 (en) | 1998-04-03 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| US6583141B1 (en) | 1998-10-09 | 2003-06-24 | Janssen Pharmaceutica, N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| IL145089A0 (en) | 1999-03-03 | 2002-06-30 | Procter & Gamble | Alkenyl-and alkynyl-containing metalloprotease inhibitors |
| WO2000071511A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| ATE310728T1 (de) | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US6416458B1 (en) * | 2000-07-12 | 2002-07-09 | Therion Research Inc. | Therapeutic flexible magnetic sheet and method |
| CA2390535C (en) | 2000-09-14 | 2008-12-02 | Edmund Gene Butts | Curling garment brush retainer |
| DE10053799A1 (de) | 2000-10-30 | 2002-05-08 | Bayer Ag | Verwendung von Tetrahydroisochinolinsulfonamiden |
| PL362992A1 (en) * | 2000-11-14 | 2004-11-15 | Smithkline Beecham P.L.C. | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| AU2002222853A1 (en) | 2000-12-07 | 2002-06-18 | Astrazeneca Ab | Therapeutic compounds |
| GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| EP1456178A1 (en) | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| JP2005517705A (ja) | 2002-02-13 | 2005-06-16 | グラクソ グループ リミテッド | ベンゼンスルホンアミド誘導体ならびにドーパミンｄ３およびｄ２受容体リガンドとしてのその使用 |
| ATE323680T1 (de) | 2002-02-13 | 2006-05-15 | Glaxo Group Ltd | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen |
| KR20040081201A (ko) | 2002-02-13 | 2004-09-20 | 글락소 그룹 리미티드 | 항정신병제로서 벤젠술폰아미드 유도체 |
| GB0210762D0 (en) | 2002-05-10 | 2002-06-19 | Glaxo Group Ltd | Compounds |
| MY133587A (en) | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
| GB0212399D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Compounds |
-
2003
- 2003-05-27 MY MYPI20031957A patent/MY133587A/en unknown
- 2003-05-27 AR ARP030101854A patent/AR040126A1/es unknown
- 2003-05-27 TW TW092114200A patent/TWI281914B/zh not_active IP Right Cessation
- 2003-05-28 AU AU2003232846A patent/AU2003232846B9/en not_active Ceased
- 2003-05-28 IL IL16533003A patent/IL165330A0/xx not_active IP Right Cessation
- 2003-05-28 ES ES03755153T patent/ES2279965T3/es not_active Expired - Lifetime
- 2003-05-28 EP EP03755153A patent/EP1511727B1/en not_active Expired - Lifetime
- 2003-05-28 JP JP2004507444A patent/JP4268126B2/ja not_active Expired - Fee Related
- 2003-05-28 PL PL03374081A patent/PL374081A1/xx not_active Application Discontinuation
- 2003-05-28 KR KR10-2004-7019172A patent/KR20050013196A/ko active IP Right Grant
- 2003-05-28 BR BR0311315-9A patent/BR0311315A/pt not_active Application Discontinuation
- 2003-05-28 NZ NZ536694A patent/NZ536694A/en not_active IP Right Cessation
- 2003-05-28 WO PCT/EP2003/005727 patent/WO2003099786A2/en active IP Right Grant
- 2003-05-28 RU RU2004138588/04A patent/RU2327690C2/ru not_active IP Right Cessation
- 2003-05-28 PT PT03755153T patent/PT1511727E/pt unknown
- 2003-05-28 SI SI200330757T patent/SI1511727T1/sl unknown
- 2003-05-28 US US10/515,998 patent/US7504392B2/en not_active Expired - Fee Related
- 2003-05-28 MX MXPA04011945A patent/MXPA04011945A/es active IP Right Grant
- 2003-05-28 DK DK03755153T patent/DK1511727T3/da active
- 2003-05-28 DE DE60311986T patent/DE60311986T2/de not_active Expired - Lifetime
- 2003-05-28 CA CA002486962A patent/CA2486962A1/en not_active Abandoned
- 2003-05-28 AT AT03755153T patent/ATE354566T1/de active
-
2004
- 2004-12-01 IS IS7577A patent/IS2482B/is unknown
- 2004-12-27 NO NO20045659A patent/NO330118B1/no not_active IP Right Cessation
-
2005
- 2005-08-23 HK HK05107403A patent/HK1075050A1/xx not_active IP Right Cessation
-
2007
- 2007-04-30 CY CY20071100580T patent/CY1107053T1/el unknown
-
2008
- 2008-06-24 US US12/144,917 patent/US20080269197A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107053T1 (el) | Αρωματικες σουλφονες και η ιατρικη τους χρηση | |
| CY1116298T1 (el) | Ενωσεις 3,4-διυποκατεστημενου 1η-πυραζολιου και χρηση αυτων ως ρυθμιστες κινασων που εξαρτωνται απο κυκλινη (cdk) και κινασης-3 συνθασης γλυκογονου (gsk-3) | |
| ATE266021T1 (de) | Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren | |
| DE69926542D1 (de) | Aminopyrazol derivate | |
| CY1105811T1 (el) | Ενωσεις ενισχυτη ταξολης | |
| CY1115657T1 (el) | Θεραπεια της μυϊκης δυστροφιας duchenne | |
| CY1105797T1 (el) | Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα | |
| ATE286506T1 (de) | Mittel zur flammschutzausrüstung | |
| EA200970311A1 (ru) | ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-α]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
| BRPI0413164A (pt) | composições bioativas compreendendo as triazinas | |
| CY1110419T1 (el) | Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| CY1108792T1 (el) | Παραγωγα διοξανιου-2-αλκυλκαρβαμικου, η παρασκευη τους και η εφαρμογη τους στην θεραπευτικη αγωγη | |
| CY1111692T1 (el) | ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ | |
| CY1108313T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
| CY1114319T1 (el) | Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4 | |
| CY1105554T1 (el) | Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης | |
| CY1111907T1 (el) | Παραγωγα πυριδινης και χρηση αυτων στην θεραπεια ψυχωτικων διαταραχων | |
| NO20023097L (no) | Heterocykliske forbindelser med sulfonamidgrupper | |
| ES2527001T3 (es) | Isoquinolinonas y quinazolinonas sustituidas | |
| CY1111428T1 (el) | Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης | |
| CY1109886T1 (el) | Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες | |
| BRPI0411366A (pt) | derivados de indazolil (indolil) maleimida substituìdos como inibidores de cinase | |
| CY1105113T1 (el) | Παραγωγα της αρυλικης (ή ετepοαρυλικης) αζολυλκαρβυνολης για την αντιμετωπιση της ακρατειας ουρων |